Who Paid My Doc
Yvonne Wirsiy
Nurse Practitioner, Primary Care Savage, MN Nurse Practitioner
NPI 1366868861 CMS profile 10851457
7426 Thorn Hill Ln, Savage, MN 55378
General payments
$322
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Yvonne Wirsiy of Savage, MN is reported in the CMS Open Payments database as having received $322 across 5 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 49th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $306 | 4 | |
| 2021 | General | $16 | 1 |
Beside peers
- Yvonne Wirsiy
- Nurse Practitioner, Primary Care median
- Middle half of Nurse Practitioner, Primary Care
- National median
In program year 2025, general payments to Yvonne Wirsiy were reported at $0. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.
Show as a table
| Year | Yvonne Wirsiy | Nurse Practitioner, Primary Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $16 | $137 | $39–$445 | $132 |
| 2022 | $306 | $139 | $44–$421 | $149 |
| 2023 | $0 | $163 | $53–$481 | $160 |
| 2024 | $0 | $176 | $54–$511 | $164 |
| 2025 | $0 | $169 | $51–$499 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
74
Drug cost
$12,594
Branded share of claims
66.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Rybelsus Semaglutide | Brand | 12 | $11,556 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 23 | $531 | |
| Gabapentin | Generic | 14 | $244 | |
| Morphine Sulfate Er Morphine Sulfate | Brand | 14 | $207 | |
| Amlodipine Besylate | Generic | 11 | $56 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Nurse Practitioner, Primary Care in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Primary Care
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.